OKYO Pharma Limited (OKYO)
NASDAQ: OKYO · Real-Time Price · USD
1.660
-0.030 (-1.78%)
At close: Mar 6, 2026, 4:00 PM EST
1.650
-0.010 (-0.60%)
After-hours: Mar 6, 2026, 7:25 PM EST
OKYO Pharma Income Statement
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
| TTM
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| Cost of Revenue | 6.26 | 4.84 | 7.51 | 6.85 | 4.61 | 3.02 | |
| Gross Profit | -6.26 | -4.84 | -7.51 | -6.85 | -4.61 | -3.02 | |
| Research & Development | -0.01 | 2.25 | 8.24 | 6.34 | 1.61 | 0.35 | |
| Operating Expenses | -0.01 | 2.25 | 8.24 | 6.34 | 1.61 | 0.35 | |
| Operating Income | -6.25 | -7.09 | -15.75 | -13.19 | -6.22 | -3.37 | |
| Interest Expense | -0.2 | -0.87 | -1.05 | -0.1 | - | -0 | |
| Interest & Investment Income | 0.01 | 0.01 | - | - | - | - | |
| Other Non Operating Income (Expenses) | -0.01 | -0.01 | - | - | - | - | |
| EBT Excluding Unusual Items | -6.46 | -7.97 | -16.8 | -13.28 | -6.22 | -3.37 | |
| Other Unusual Items | - | - | - | - | - | -0.01 | |
| Pretax Income | -6.46 | -7.97 | -16.8 | -13.28 | -6.22 | -3.38 | |
| Income Tax Expense | -1.85 | -3.26 | 0.02 | -0.01 | -0.79 | -0.02 | |
| Earnings From Continuing Operations | -4.61 | -4.71 | -16.83 | -13.27 | -5.43 | -3.35 | |
| Net Income | -4.61 | -4.71 | -16.83 | -13.27 | -5.43 | -3.35 | |
| Net Income to Common | -4.61 | -4.71 | -16.83 | -13.27 | -5.43 | -3.35 | |
| Shares Outstanding (Basic) | 41 | 39 | 29 | 22 | 15 | 10 | |
| Shares Outstanding (Diluted) | 41 | 39 | 29 | 22 | 15 | 10 | |
| Shares Change (YoY) | 24.46% | 34.57% | 31.84% | 47.74% | 45.55% | 12.98% | |
| EPS (Basic) | -0.11 | -0.12 | -0.57 | -0.60 | -0.36 | -0.32 | |
| EPS (Diluted) | -0.11 | -0.12 | -0.57 | -0.60 | -0.36 | -0.32 | |
| Free Cash Flow | -3.1 | -1.81 | -9.49 | -7.7 | -5.47 | -1.61 | |
| Free Cash Flow Per Share | -0.07 | -0.05 | -0.32 | -0.35 | -0.36 | -0.15 | |
| EBITDA | -6.25 | -7.09 | -15.75 | -13.18 | -6.22 | -3.36 | |
| D&A For EBITDA | 0 | 0 | 0 | 0 | 0 | 0 | |
| EBIT | -6.25 | -7.09 | -15.75 | -13.19 | -6.22 | -3.37 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.